

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
INITIATION OF PHASE I CLINICAL TRIAL AND COMPLETION OF
FIRST PATIENT ENROLLMENT FOR HAEMOPHILUS INFLUENZAE
TYPE B CONJUGATE VACCINE, FREEZE-DRIED

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

The Company is pleased to announce that, the phase I clinical trial for the Haemophilus Influenzae Type b (the “**Hib**”) Conjugate Vaccine, Freeze-dried (the “**Hib Vaccine**”) developed by the Company, was officially initiated recently and the first trial patient case has been formally enrolled.

As a gram-negative bacillus, haemophilus influenzae is one of the most prevalent pathogens of acute lower respiratory tract infections in children, and is classified into encapsulated and unencapsulated strains, both of which can induce infections. The unencapsulated strain often causes diseases like otitis media and sinusitis, which is mainly due to the spread of colonising bacteria from the nasopharynx to neighbouring areas; infections secondary to bloodstream invasion are usually caused by the encapsulated strains. Encapsulated strains are classified according to the chemical composition of the capsular polysaccharide, and 6 serotypes have been identified, of which about 95% of invasive haemophilus influenzae disease is caused by type b.

The Hib Vaccine is a covalent combination of purified Hib capsular polysaccharide and tetanus toxoid protein in a freeze-dried dosage, which is expected to induce humoral immunity against Hib after vaccination and provide protection to the vaccinees. The Company is developing a combined vaccine based on the DTcP components, of which the Hib Vaccine candidate is one of the components. As a vaccine that has not been approved for commercialisation, it is necessary to accumulate a certain amount of clinical data in order to support the registration and application of the combined vaccine based on the DTcP components in the future.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, November 15, 2024

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Shuifa GUI, Mr. Jianzhong LIU and Mr. Yiu Leung Andy CHEUNG as independent non-executive Directors.